Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Formation Bio
Biotech
Formation Bio makes $605M play for Lynk's TYK2 inhibitor
Lynk’s TYK2 program will be developed by Formation’s freshly formed subsidiary, dubbed Bleecker Bio.
Gabrielle Masson
Dec 10, 2025 10:27am
Fierce Biotech's 2025 Fierce 15
Sep 22, 2025 8:00am
CatalYm catalyzes C-suite shake-up—Chutes & Ladders
Sep 19, 2025 8:30am
Sanofi signs €545M deal to explore Formation’s JAK/SYK inhibitor
Jun 23, 2025 9:47am
Sanofi vaccine vet vaults to GSK—Chutes & Ladders
Jun 13, 2025 8:30am
Biotech's top money raisers: 2024
Mar 3, 2025 5:00am
